High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients

Histology and Histopathology

Volumn 27, Issue 2, 2012, Pages 197-207

  Park, Sanghui ^a,e   Choi, Yoon La ^b   Sung, Chang Ok ^b   An, Jungsuk ^a   Seo, Jinwon ^c   Ahn, Myung Ju ^b   Ahn, Jin Seok ^b   Park, Keunchil ^b   Shin, Young Kee ^d   Erkin, Ozgur Cem ^d   Song, Kyung ^d   Kim, Jhingook ^b   Shim, Young Mog ^b   Han, Joungho ^b  

^a Gachon University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Ewha Womans University School of Medicine   (South Korea)

Author keywords

EGFR; FISH; Gene copy number; MET; Non small cell lung cancer

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

AGED; ARTICLE; BIOSYNTHESIS; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; TISSUE MICROARRAY; TREATMENT OUTCOME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84863229341     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Arteaga C.L. (2007). HER3 and mutant EGFR meet MET. Nat. Med. 13, 675-677.
2. Beau-Faller M., Ruppert A.M., Voegeli A.C., Neuville A., Meyer N., Guerin E., Legrain M., Mennecier B., Wihlm J.M., Massard G., Quoix E., Oudet P. and Gaub M.P. (2008). MET gene copy number in nonsmall cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J. Thorac. Oncol. 3, 331-339.
3. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., Sgroi D.C., Muir B., Riemenschneider M.J., Iacona R.B., Krebs A.D., Johnson D.H., Giaccone G., Herbst R.S., Manegold C., Fukuoka M., Kris M.G., Baselga J., Ochs J.S. and Haber D.A. (2005). Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081-8092.
4. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovin, V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn P.A. Jr and Varella-Garcia M. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643-655.
5. Cappuzzo F., Janne P.A., Skokan M., Finocchiaro G., Rossi E., Ligorio C., Zucali P.A., Terracciano L., Toschi L., Roncalli M., Destro A., Incarbone M., Alloisio M., Santoro A. and Varella-Garcia M. (2009). MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 20, 298-304.
6. Cappuzzo F., Marchetti A., Skokan M., Rossi E., Gajapathy S., Felicioni L., Del Grammastro M., Sciarrotta M.G., Buttitta F., Incarbone M., Toschi L., Finocchiaro G., Destro A., Terracciano L., Roncalli M., Alloisio M., Santoro A. and Varella-Garcia M. (2009). Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27, 1667-1674.
7. Dziadziuszko R., Hirsch F.R., Varella-Garcia M. and Bunn P.A. Jr (2006). Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how? Clin. Cancer Res. 12, 4409s-4415s.
8. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., Ince W.L., Janne P.A., Januario T., Johnson D.H., Klein P., Miller, V.A., Ostland M.A., Ramies D.A., Sebisanovic D., Stinson J.A., Zhang Y.R., Seshagiri S. and Hillan K.J. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23, 5900-5909.
9. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C. and Janne P.A. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
10. Go H., Jeon Y.K., Park H.J., Sung S.W., Seo J.W. and Chung D.H. (2010). High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J. Thorac. Oncol. 5, 305-313.
11. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., Kris M.G., Tran H.T., Klein P., Li X., Ramies D., Johnson D.H. and Miller V.A. (2005). TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899.
12. Hirsch F.R., Varella-Garcia M., Bunn P.A. Jr, Di Maria M.V., Veve R., Bremmes R.M., Baron A.E., Zeng C. and Franklin W.A. (2003). Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798-3807.
13. Hirsch F.R., Varella-Garcia M., Bunn P.A. Jr, Franklin W.A., Dziadziuszko R., Thatcher N., Chang A., Parikh P., Pereira J.R., Ciuleanu T., von Pawel J., Watkins C., Flannery A., Ellison G., Donald E., Knight L., Parums D., Botwood N. and Holloway B. (2006). Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034-5042.
14. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., Dziadziuszko R., Gumerlock P., Chansky K., West H., Gazdar A.F., Crino L., Gandara D.R., Franklin W.A. and Bunn P.A., Jr. (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 18, 752-760.
15. Ichimura E., Maeshima A., Nakajim, T. and Nakamura T. (1996). Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn. J. Cancer Res. 87, 1063-1069.
16. Kanteti R., Yala S., Ferguson M.K. and Salgia R. (2009). MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J. Environ. Pathol. Toxicol. Oncol. 28, 89-98.
17. Knudsen B.S. and Vande Woude G. (2008). Showering c-METdependent cancers with drugs. Curr. Opin. Genet. Dev. 18, 87-96.
18. Ma P.C., Kijima T., Maulik G., Fox E.A., Sattler M., Griffin J.D., Johnson B.E. and Salgia R. (2003). c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 63, 6272-6281.
19. Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., Fox E.A., Hansen M., Schaefer E., Naoki K., Lader A., Richards W., Sugarbaker D., Husain A.N., Christensen J.G. and Salgia R. (2005). Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479-1488.
20. Ma P.C., Tretiakova M.S., MacKinnon A.C., Ramnath N., Johnson C., Dietrich S., Seiwert T., Christensen J.G., Jagadeeswaran R., Krausz T., Vokes E.E., Husain A.N. and Salgia R. (2008). Expression and mutational analysis of MET in human solid cancers. Gene. Chromosomes Cancer 47, 1025-1037.
21. McDermott U., Sharma S.V., Dowell L., Greninger P., Montagut C., Lamb J., Archibald H., Raudales R., Tam A., Lee D., Rothenberg S.M., Supko J.G., Sordella R., Ulkus L.E., Iafrate A.J., Maheswaran, S., Njauw C.N., Tsao H., Drew L., Hanke J.H., Ma X.J., Erlander M.G., Gray N.S., Haber D.A. and Settleman J. (2007). Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl. Acad. Sci. USA 104, 19936-19941.
22. Nakamura Y., Niki T., Goto A., Morikawa T., Miyazawa K., Nakajima J. and Fukayama M. (2007). c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 98, 1006-1013.
23. Nakamura Y., Matsubara D., Goto A., Ota S., Sachiko O., Ishikawa S., Aburatani H., Miyazawa K., Fukayama M. and Niki T. (2008). Constitutive activation of c-Met is correlated with c-Met overexpression and dependent on cell-matrix adhesion in lung adenocarcinoma cell lines. Cancer Sci. 99, 14-22.
24. Nguyen K.S., Kobayashi S. and Costa D.B. (2009). Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 10, 281-289.
25. Okuda K., Sasaki H., Yukiue H., Yano M. and Fujii Y. (2008). Met gene copy number predicts the prognosis for completely resected nonsmall cell lung cancer. Cancer Sci. 99, 2280-2285.
26. Ramalingam S.S., Owonikoko T.K. and Khuri F.R. (2011). Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J. Clin. 61, 91-112.
27. Suda K., Murakami I., Katayama T., Tomizawa K., Osada H., Sekido Y., Maehara Y., Yatabe Y. and Mitsudomi T. (2010). Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 16, 5489-5498.
28. Toschi L. and Cappuzzo F. (2010). Clinical implications of MET gene copy number in lung cancer. Future Oncol. 6, 239-247.
29. Travis W.D., Brambilla E. and Muller-Hermelink H.K. (2004). World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press. Lyon.
30. Tsao M.S., Sakurada A., Cutz J. C., Zhu C.Q., Kamel-Reid S., Squire J., Lorimer I., Zhang T., Liu N., Daneshmand M., Marrano P., da Cunha Santos G., Lagarde A., Richardson F., Seymour L., Whitehead M., Ding K., Pater J. and Shepherd F. A. (2005). Erlotinib in lung cancer -molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144.
31. Varella-Garcia M. (2006). Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn. Pathol. 1, 19.
32. Yoshida T., Zhang G. and Haura E.B. (2010). Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem. Pharmacol. 80, 613-623.